CRISPR

CRISPR1-depdc5

ID
ZDB-CRISPR-190104-1
Name
CRISPR1-depdc5
Previous Names
None
Target
Sequence
5' - TGAGGATCATGAGCAAT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
udm102 depdc5
Expression
Gene expression in Wild Types + CRISPR1-depdc5
No data available
Phenotype
Phenotype resulting from CRISPR1-depdc5
No data available
Phenotype of all Fish created by or utilizing CRISPR1-depdc5
Phenotype Fish Conditions Figures
whole organism decreased life span, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 1 with imageFig. 5 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: pentetrazol, chemical treatment by environment: vigabatrin Fig. 6 with image from Swaminathan et al., 2018
musculoskeletal movement decreased occurrence, abnormal depdc5udm102/udm102 (TL) control Fig. 2 with imageFig. 5 with image from Swaminathan et al., 2018
optic tectum neuronal action potential increased occurrence, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with image from Swaminathan et al., 2018
brain mt-cyb expression amount, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
brain gabrg2 expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
brain efnb3b expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
TOR signaling increased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 7 with image from Swaminathan et al., 2018
whole organism decreased life span, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 5 with image from Swaminathan et al., 2018
brain slc12a5b expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
whole organism depdc5 expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 1 with image from Swaminathan et al., 2018
brain mt-co2 expression amount, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
whole organism life span, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
whole organism decreased length, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 1 with image from Swaminathan et al., 2018
brain slc6a11b expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
swimming increased occurrence, exacerbated depdc5udm102/udm102 (TL) chemical treatment by environment: pentetrazol Fig. 2 with imageFig. 5 with imageFig. 6 with image from Swaminathan et al., 2018
whole organism lethal (sensu genetics), abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 1 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
GABAergic neuron axon arborization decreased occurrence, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 4 with imageFig. 5 with image from Swaminathan et al., 2018
whole organism ab1-rps6 labeling amount, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
brain slc6a11b expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
brain sema3ab expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
brain plxna2 expression decreased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
whole organism ab1-rps6 labeling increased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 7 with image from Swaminathan et al., 2018
optic tectum ab1-rps6 labeling increased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with image from Swaminathan et al., 2018
optic tectum negative regulation of neuronal action potential decreased occurrence, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with image from Swaminathan et al., 2018
brain mt-co2 expression increased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: vigabatrin Fig. 6 with image from Swaminathan et al., 2018
brain mt-cyb expression increased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 7 with image from Swaminathan et al., 2018
GABAergic neuron axon arborization decreased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 5 with image from Swaminathan et al., 2018
whole organism ab1-rps6 labeling increased amount, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with imageFig. 5 with imageFig. 7 with image from Swaminathan et al., 2018
swimming decreased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: baclofen Fig. 6 with image from Swaminathan et al., 2018
musculoskeletal movement occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
TOR signaling increased occurrence, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with imageFig. 5 with imageFig. 7 with image from Swaminathan et al., 2018
swimming decreased occurrence, abnormal depdc5udm102/udm102 (TL) standard conditions Fig. 2 with imageFig. 5 with image from Swaminathan et al., 2018
brain efnb3b expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: pentetrazol, chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
GABAergic neuron axon arborization decreased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
brain plxna2 expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid, chemical treatment by environment: pentetrazol Fig. 5 with image from Swaminathan et al., 2018
brain slc12a5b expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
swimming decreased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: baclofen, chemical treatment by environment: muscimol Fig. 6 with image from Swaminathan et al., 2018
brain gabrg2 expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
brain sema3ab expression decreased amount, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 7 with image from Swaminathan et al., 2018
TOR signaling occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: sirolimus Fig. 5 with image from Swaminathan et al., 2018
swimming occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 5 with image from Swaminathan et al., 2018
musculoskeletal movement occurrence, ameliorated depdc5udm102/udm102 (TL) chemical treatment by environment: gamma-aminobutyric acid Fig. 5 with image from Swaminathan et al., 2018
swimming decreased occurrence, abnormal depdc5udm102/udm102 (TL) chemical treatment by environment: muscimol Fig. 6 with image from Swaminathan et al., 2018
whole organism depdc5 expression decreased amount, abnormal depdc5udm102/+ (TL) standard conditions Fig. 1 with image from Swaminathan et al., 2018
whole organism ab1-rps6 labeling increased amount, abnormal depdc5udm102/+ (TL) standard conditions Fig. 2 with image from Swaminathan et al., 2018
Citations